Researchers sourcing CagriSema for laboratory use have higher quality-verification expectations in 2026 than at any prior point. Life Link Research supplies research-grade CagriSema with six-panel third-party independent COA on every batch, US domestic shipping, and COA documentation available before purchase.
Specifications
| Compound | CagriSema (Cagrilintide + Semaglutide co-formulation) |
| Available size | 10mg total ($156) |
| Components | Semaglutide (GLP-1R agonist) + Cagrilintide (long-acting amylin analog) |
| Receptor targets | GLP-1R + AMYR (amylin receptor) |
| Purity | ≥98% each component by HPLC (third-party independent lab) |
| Quality panel | HPLC + mass spec + LAL endotoxin + sterility + moisture + amino acid composition |
| COA | Available before purchase, batch-matched |
| Shipping | US domestic, 2-4 business days |
Why CagriSema Is Distinct from Tirzepatide
CagriSema and tirzepatide both combine a GLP-1 receptor agonist with a second mechanism — but the second mechanisms differ fundamentally. Tirzepatide is a dual agonist molecule: semaglutide-like GLP-1R activity plus GIP receptor agonism in one peptide chain. CagriSema is a co-formulation of two separate peptides: semaglutide for GLP-1R + cagrilintide for amylin receptor (AMYR). The research implication: CagriSema and tirzepatide are complementary tools for studying different multi-receptor architectures, not substitutes.
Why Third-Party COA Matters for CagriSema
CagriSema’s two-peptide co-formulation creates additional quality control complexity. Both peptides must meet purity standards, and the ratio between the two components must match the formulation specification. Independent third-party testing verifies each component’s individual purity, each component’s correct molecular weight via mass spectrometry, and the actual ratio of semaglutide to cagrilintide in the vial. Vendor-internal testing alone cannot reliably confirm the formulation ratio.
Research Resources
FAQs
Is CagriSema legal to buy for research?
Yes as of May 2026 under the “for research purposes only” framework. The SAFE Drugs Act (H.R. 6509) would affect compounds identical to FDA-approved drugs (the semaglutide component).
How is CagriSema different from tirzepatide?
CagriSema is a co-formulation of two peptides; tirzepatide is a single dual-agonist molecule. Different molecular architecture, different receptor combinations.
For research purposes only. Not for human use.